Drug Profile

EHT 102

Alternative Names: EHT-102

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Euhearing Therapeutics
Class Gene therapies
Mechanism of Action Gene transference; OTOF protein expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Hearing loss

Most Recent Events

17 Dec 2025 Preclinical trials in Hearing loss in China (Otic) prior to December 2025
17 Dec 2025 Shanghai Euhearing Therapeutics plans a phase I/II trial for Hearing loss (In infants, In children, In adolescents) in USA and China (Otic, Injection) in March 2026 (NCT07288580)
06 May 2025 Shanghai Euhearing Therapeutics has patents pending for 'Dual-vector system for treating hearing impairment and use thereof' in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com